Shionogi quarterly reports update from Oct 2019 stated that they returned the rights to S-004992 back to C&O due to pre-clinical study results.
Shinonogi & Co., Ltd is developing S-004992 in collaboration with its originator C&O Pharmaceutical Technology (Holdings) Limited of China, a Shionogi’s subsidiary. Now in GLP studies, S-004992 may enter clinical studies in April 2020.